Compare iShares Russell 2000 ETF (IWM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs Tango Therapeutics Inc. — how do they compare? iShares Russell 2000 ETF trades at $271.97 (market cap $77.75B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares Russell 2000 ETF is far larger — about 20.7× Tango Therapeutics Inc.'s market cap, and iShares Russell 2000 ETF is more actively traded (27,728,271 versus 9,619,106). Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and Tango Therapeutics Inc. for 0 Days on average.
| IWM | TNGX | |
|---|---|---|
Market Cap | $77.75B | $3.75B |
Volume | 27,728,271 | 9,619,106 |
52-Week High | $305.06 | $32.90 |
52-Week Low | $229.13 | $7.50 |
Typical Hold Time | 83 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM trades at $276.71, down 0.42% with bearish technical signals from moving averages. The ETF faces headwinds as small-caps underperform large-caps, with recent Fed rate hikes pressuring the sector. Technical indicators show oversold conditions with RSI at 38.61, while support sits at $276. Recent news highlights IWM's decade-long underperformance versus the S&P 500, raising questions about the small-cap premium.
The outlook remains cautious given macroeconomic pressures and sector rotation away from small-caps. Higher interest rates typically disadvantage small companies with greater borrowing needs, while broader market concentration in tech giants reduces small-cap participation. However, current valuations may offer long-term value if economic conditions stabilize.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
